Explore / Peer-reviewed article
Peer-reviewed articleOpen access

Effects of psilocybin versus escitalopram on rumination and thought suppression in depression.

Barba TiD, Buehler S, Kettner H, Radu CiD, Cunha BG, Nutt DJ, Erritzoe DiD, Roseman L, Carhart-Harris RiD

BJPsych openSep 6, 2022License: open accessUnited Kingdom, United States43 citationsDOI: 10.1192/bjo.2022.565

Abstract

<h4>Background</h4>Major depressive disorder is often associated with maladaptive coping strategies, including rumination and thought suppression.<h4>Aims</h4>To assess the comparative effect of the selective serotonin reuptake inhibitor escitalopram, and the serotonergic psychedelic psilocybin (COMP360), on rumination and thought suppression in major depressive disorder.<h4>Method</h4>Based on data derived from a randomised clinical trial (<i>N</i> = 59), we performed exploratory analyses on the impact of escitalopram versus psilocybin (i.e. condition) on rumination and thought suppression from 1 week before to 6 weeks after treatment inception (i.e. time), using mixed analysis of variance. Condition responder versus non-responder subgroup analyses were also done, using the standard definition of ≥50% symptom reduction.<h4>Results</h4>A time×condition interaction was found for rumination (F(1, 56) = 4.58, <i>P</i> = 0.037) and thought suppression (F(1,57) = 5.88, <i>P</i> = 0.019), with <i>post hoc</i> tests revealing significant decreases exclusively in the psilocybin condition. When analysing via response, a significant time×condition×response interaction for thought suppression (F(1,54) = 8.42, <i>P</i> = 0.005) and a significant time×response interaction for rumination (F(1,54) = 23.50, <i>P</i> < 0.001) were evident. Follow-up tests revealed that decreased thought suppression was exclusive to psilocybin responders, whereas rumination decreased in both responder groups. In the psilocybin arm, decreases in rumination and thought suppression correlated with ego dissolution and session-linked psychological insight.<h4>Conclusions</h4>These data provide further evidence on the therapeutic mechanisms of psilocybin and escitalopram in the treatment of depression.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinDepression

Keywords

AntidepressantsDepressive DisordersRandomised Controlled TrialNovel Central Nervous System DrugsPharmaceutical Drug Trial

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

This study's objects

Directly linked records, matched by DOI, trial reference, or registry, not just topic.